Purpose
To assess the clinical performance of the three-dimensional,
free-breathing, Magnetization Transfer Contrast Bright-and-black blOOd
phase-SensiTive (MTC-BOOST) sequence in adult congenital heart disease
(ACHD).
Materials and Methods
In this prospective study, participants with ACHD undergoing cardiac MRI
between July 2020 and March 2021 were scanned with the clinical
T2-prepared balanced steady-state free precession sequence and proposed
MTC-BOOST sequence. Four cardiologists scored their diagnostic
confidence on a four-point Likert scale for sequential segmental
analysis on images acquired with each sequence. Scan times and
diagnostic confidence were compared using the Mann-Whitney test. Coaxial
vascular dimensions at three anatomic landmarks were measured, and
agreement between the research sequence and the corresponding clinical
sequence was assessed with Bland-Altman analysis.
Results
The study included 120 participants (mean age, 33 years ± 13 [SD];
65 men). The mean acquisition time of the MTC-BOOST sequence was
significantly lower compared with that of the conventional clinical
sequence (9 minutes ± 2 vs 14 minutes ± 5;
P
< .001). Diagnostic confidence was higher
for the MTC-BOOST sequence compared with the clinical sequence (mean,
3.9 ± 0.3 vs 3.4 ± 0.7;
P
< .001).
Narrow limits of agreement and mean bias less than 0.08 cm were found
between the research and clinical vascular measurements.
Conclusion
The MTC-BOOST sequence provided efficient, high-quality, and contrast
agent–free three-dimensional whole-heart imaging in ACHD, with
shorter, more predictable acquisition time and improved diagnostic
confidence compared with the reference standard clinical sequence.
Keywords:
MR Angiography, Cardiac
Supplemental material is available for this
article.
Published under a CC BY 4.0 license